Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use of gene transfer

Abstract

Novel lipid-nucleic acid particulate complexes which are useful for in vitro or in vivo gene transfer are described. The particles can be formed using either detergent dialysis methods or methods which utilize organic solvents. Upon removal of a solubilizing component (i.e., detergent or an organic solvent) the lipid-nucleic acid complexes form particles wherein the nucleic acid is serum-stable and is protected from degradation. The particles thus formed have access to extravascular sites and target cell populations and are suitable for the therapeutic delivery of nucleic acids.

1 . A hydrophobic lipid-nucleic acid complex consisting essentially of cationic lipids and nucleic acids, said complex being charge-neutralized and soluble in organic solvents.  
     
     
         2 . A complex in accordance with  claim 1 , wherein said nucleic acid is a plasmid.  
     
     
         3 . A complex in accordance with  claim 1 , wherein said cationic lipids are members selected from the group consisting of DODAC, DDAB, DOTMA, DOSPA, DMRIE, DOGS and combinations thereof.  
     
     
         4 . A method for the preparation of lipid-nucleic acid particles, comprising: 
 (a) contacting nucleic acids with a solution comprising non-cationic lipids and a detergent to form a nucleic acid-lipid mixture;    (b) contacting cationic lipids with said nucleic acid-lipid mixture to neutralize the negative charge of said nucleic acids and form a charge-neutralized mixture comprising detergent, nucleic acids and lipids; and    (c) removing said detergent from said charge-neutralized mixture to provide said lipid-nucleic acid particles in which said nucleic acids are protected from degradation.    
     
     
         5 . A method in accordance with  claim 4 , wherein said solution of step (a) further comprises an organic solvent.  
     
     
         6 . A method in accordance with  claim 4 , wherein said cationic lipids are members selected from the group consisting of DODAC, DDAB, DOTMA, DOSPA, DMRIE, DOGS and combinations thereof.  
     
     
         7 . A method in accordance with  claim 4 , wherein said non-cationic lipids are selected from the group consisting of ESM, DOPE, polyethylene glycol-based polymers and combinations thereof.  
     
     
         8 . A method in accordance with  claim 4 , wherein said detergent is octyl-β-D-glucopyranoside, said cationic lipid is DODAC, said non-cationic lipid is ESM, and said detergent is removed by dialysis.  
     
     
         9 . A method in accordance with  claim 8 , wherein said non-cationic lipids are combinations of ESM and PEG-Ceramide.  
     
     
         10 . A method for introducing a nucleic acid into a cell, comprising; 
 (a) preparing a lipid-nucleic acid particle according to the method of  claim 4;  and    (b) contacting said cell with said lipid-nucleic acid particle for a period of time sufficient to introduce said nucleic acid into said cell.    
     
     
         11 . A method in accordance with  claim 11 , wherein said lipid-nucleic acid particle comprises a plasmid, DODAC and ESM.  
     
     
         12 . A method for the preparation of lipid-nucleic acid particles, comprising: 
 (a) contacting an amount of cationic lipids with nucleic acids in a solution; said solution comprising of from about 15-35% water and about 65-85% organic solvent and said amount of cationic lipids being sufficient to produce a +/−charge ratio of from about 0.85 to about 2.0, to provide a hydrophobic, charge-neutralized lipid-nucleic acid complex;    (b) contacting said hydrophobic lipid-nucleic acid complex in solution with non-cationic lipids, to provide a lipid-nucleic acid mixture; and (c) removing said organic solvents from said mixture to provide said lipid-nucleic acid particles in which said nucleic acids are protected from degradation.    
     
     
         13 . A method in accordance with  claim 12 , wherein said cationic lipids are members selected from the group consisting of DODAC, DDAB, DOTMA, DOSPA, DMRIE, DOGS and combinations thereof.  
     
     
         14 . A method in accordance with  claim 12 , wherein said non-cationic lipids are members selected from the group consisting of ESM, DOPE, polyethylene glycol-based polymers and combinations thereof.  
     
     
         15 . A method in accordance with  claim 12 , wherein said organic solvents are members selected from the group consisting of methanol, chloroform, methylene chloride, ethanol, diethyl ether and combinations thereof.  
     
     
         16 . A method in accordance with  claim 12 , wherein said nucleic acid is a plasmid, said cationic lipid is a member selected from the group consisting of DODAC, DDAB, DOTMA, DOSPA, DMRIE, DOGS and combinations thereof, said non-cationic lipid is a member selected from the group consisting of ESM, DOPE, polyethylene glycol-based polymers and combinations thereof, and said organic solvent is a member selected from the group consisting of methanol, chloroform, methylene chloride, ethanol, diethyl ether and combinations thereof.  
     
     
         17 . A method for introducing a nucleic acid into a cell, comprising; 
 (a) preparing a lipid-nucleic acid particle according to the method of  claim 13;  and    (b) contacting said cell with said lipid-nucleic acid particle for a period of time sufficient to introduce said nucleic acid into said cell.    
     
     
         18 . A lipid-nucleic acid particle prepared according to  claim 4 .  
     
     
         19 . A lipid-nucleic acid particle prepared according to  claim 12 .  
     
     
         20 . A method for the preparation of serum-stable plasmid-lipid particles, comprising: 
 (a) combining a plasmid with cationic lipids in a detergent solution to provide a coated plasmid-lipid complex;    (b) contacting non-cationic lipids with said coated plasmid-lipid complex to provide a solution comprising detergent, a plasmid-lipid complex and non-cationic lipids; and    (c) removing said detergent from said solution of step (b) to provide a solution of serum-stable plasmid-lipid particles, wherein said plasmid is encapsulated in a lipid bilayer and said particles are serum-stable and have a size of from about 50 to about 150 nm.    
     
     
         21 . A method in accordance with  claim 20 , wherein said removing is by dialysis.  
     
     
         22 . A method in accordance with  claim 20 , wherein step (b) further comprises adding a polyethylene glycol-lipid conjugate.  
     
     
         23 . A method in accordance with  claim 22 , wherein said polyethylene glycol-lipid conjugate is a PEG-ceramide conjugate.  
     
     
         24 . A method in accordance with  claim 20 , further comprising; 
 (d) sizing said particles to achieve a uniform particle size.    
     
     
         25 . A method in accordance with  claim 20 , wherein said cationic lipids are selected from the group consisting of DODAC, DDAB, DOTAP, DOTMA, DOSPA DOGS, DC-Chol and combinations thereof.  
     
     
         26 . A method in accordance with  claim 20 , wherein said non-cationic lipids are selected from the group consisting of DOPE, POPC, EPC and combinations thereof.  
     
     
         27 . A method in accordance with  claim 20 , wherein said detergent solution comprises a detergent having a critical micelle concentration of between about 20 mM and 50 mM.  
     
     
         28 . A method in accordance with  claim 8 , wherein said detergent is n-octyl-β-D-glucopyranoside.  
     
     
         29 . A method for the preparation of serum-stable plasmid-lipid particles, comprising; 
 (a) preparing a mixture comprising cationic lipids and non-cationic lipids in an organic solvent;    (b) contacting an aqueous solution of plasmid with said mixture prepared in step (a) to provide a clear single phase; and    (c) removing said organic solvent to provide a suspension of plasmid-lipid particles, wherein said plasmid is encapsulated in a lipid bilayer, and said particles are stable in serum and have a size of from about 50 to about 150 nm.    
     
     
         30 . A method in accordance with  claim 29 , wherein said non-cationic lipids comprise a polyethylene glycol-lipid conjugate.  
     
     
         31 . A method in accordance with  claim 30 , wherein said polyethylene glycol-lipid conjugate is a PEG-ceramide conjugate.  
     
     
         32 . A method in accordance with  claim 29 , wherein said cationic lipids are selected from the group consisting of DODAC, DDAB, DOTAP, DOTMA, DOSPA, DOGS, DC-Chol and combinations thereof.  
     
     
         33 . A method in accordance with  claim 29 , wherein said non-cationic lipids are selected from the group consisting of DOPE, POPC, EPC and combinations thereof.  
     
     
         34 . A plasmid-lipid particle prepared according to  claim 20 .  
     
     
         35 . A method for introducing a plasmid into a cell, comprising; 
 (a) preparing a plasmid-lipid particle according to the method of  claim 20;  and    (b) contacting said cell with said plasmid-lipid particle for a period of time sufficient to introduce said plasmid into said cell.    
     
     
         36 . A method in accordance with  claim 35 , wherein said plasmid-lipid particle comprises a plasmid, DODAC, POPC and a PEG-Ceramide selected from the group consisting of PEG-Cer-C 20  and PEG-Cer-C 14 .  
     
     
         37 . A method in accordance with  claim 35 , wherein said plasmid-lipid particle comprises a plasmid, DODAC, DOPE and a PEG-Ceramide selected from the group consisting of PEG-Cer-C 20  and PEG-Cer-C 14 .  
     
     
         38 . A plasmid-lipid particle prepared according to  claim 29 .  
     
     
         39 . A method for introducing a plasmid into a cell, comprising; 
 (a) preparing a plasmid-lipid particle according to the method of  claim 29;  and    (b) contacting said cell with said plasmid-lipid particle for a period of time sufficient to introduce said plasmid into said cell.    
     
     
         40 . A method in accordance with  claim 39 , wherein said plasmid-lipid particle comprises a plasmid, DODAC, POPC and a PEG-Ceramide selected from the group consisting of PEG-Cer-C 20  and PEG-Cer-C 14 .  
     
     
         41 . A method in accordance with  claim 39 , wherein said plasmid-lipid particle comprises a plasmid, DODAC, DOPE and a PEG-Ceramide selected from the group consisting of PEG-Cer-C 20  and PEG-Cer-C 14 .